ISSN: 0022-1198
CODEN: JFSCA
Published Online: 1 January 1975
Page Count: 3

Carisoprodol-Related Death in a Child
Morehead, CD
RELA Schering Corp., N.J.

Adams, HR
Toxicology and Pharmacology Laboratory, Department of Clinical Pathology, Scott and White Clinic, Texas

Kerzee, T
Chief, Scott and White Clinic, Texas

(Received 15 April 1974; accepted 2 August 1974)

Abstract

Carisoprodol (N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate), a congener of meprobramate, is recommended by its manufacturers as a centrally acting musculoskeletal relaxant with mild anticholinergic, antipyretic, and analgesic properties. Many authorities maintain that the beneficial effects of carisoprodol noted in the treatment of patients with muscle spasm of local origin are related more to modification of central pain perception than they are to muscle relaxant properties [1,2]. Drowsiness, vertigo, weakness, and lassitude have accompanied carisoprodol therapy, but these adverse effects occur infrequently in adults who are taking recommended dosages of 250 or 350 mg four times daily [3].

Keywords:

Paper ID: JFS10259J
DOI: 10.1520/JFS10259J
ASTM International is a member of CrossRef.